EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death receptor-1 inhibitors for unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Yonghong He, Yuexi Liu, Jie Xu, Yanan He

Translational Cancer Research · 2025-08 · 14 (8) · 4976-4988

DOI: 10.21037/tcr-2025-798 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Translational Cancer Research, 2025-08. Verfasst von Yonghong He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery, The People's Hospital of Jiangyou, Jiangyou, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

More than 60% of patients with hepatocellular carcinoma (HCC) are diagnosed at the intermediate-advanced stages, which are not amenable to surgical resection and ablation. The optimal treatment plan for patients with unresectable HCC remains controversial. This study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKI) plus programmed death receptor-1 (PD-1) inhibitors (TACE + TKI + PD-1) versus TACE combined with TKI (TACE + TKI) among patients with unresectable HCC.

Methods

A comprehensive search of the PubMed, EMBASE and the Cochrane Library databases was performed, and all studies related to TACE + TKI + PD-1 and TACE + TKI for treatment of HCC were included. We calculated risk ratio (RR) and mean difference for dichotomous and continuous outcomes. Data were analyzed using RevMan5.4 and Stata 17.0. We conducted a subgroup analysis based on specific types of TKI.

Results

A total of 12 retrospective studies were included in the analysis, involving 1,078 patients in the TACE + TKI + PD-1 group and 1,332 in the TACE + TKI group. Compared with the TACE + TKI group, the TACE + TKI + PD-1 group showed prolonged overall survival [RR =7.39, 95% confidence interval (CI): 5.69-9.08, P

Schlagwörter

Stichwörter der Autor:innen

Transcatheter arterial chemoembolizationcamrelizumabhepatocellular carcinoma (HCC)programmed death receptor-1 inhibitors (PD-1 inhibitors)tyrosine kinase inhibitors (TKIs)

Autor:innen und Institutionen

  • Hepatobiliary Surgery, The People's Hospital of Jiangyou, Jiangyou, China.
  • The Second College of Clinical Medicine, Dalian Medical University, Dalian, China.

Zitieren

APA

He, Y., Liu, Y., Xu, J., & He, Y. (2025). Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death receptor-1 inhibitors for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Translational Cancer Research, 14(8), 4976-4988. https://doi.org/10.21037/tcr-2025-798

Vancouver

He Y, Liu Y, Xu J, He Y. Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death receptor-1 inhibitors for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Translational Cancer Research. 2025;14(8):4976-4988. doi:10.21037/tcr-2025-798

BibTeX
@article{He2025,
  author = {He, Yonghong and Liu, Yuexi and Xu, Jie and He, Yanan},
  title = {Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death receptor-1 inhibitors for unresectable hepatocellular carcinoma: a systematic review and meta-analysis},
  journal = {Translational Cancer Research},
  year = {2025},
  volume = {14},
  number = {8},
  pages = {4976--4988},
  doi = {10.21037/tcr-2025-798}
}
Kostenlos starten →